Pfizer (NYSE:PFE) today announced the completion of its acquisition of privately held NextWave Pharmaceuticals, which focuses its drug research and development efforts on products designed to treat attention deficit hyperactivity disorder (ADHD).
After closing the acquisition, Pfizer now holds the exclusive North American rights to distribute Quillivant XR, the first once-daily liquid medication approved by the FDA to treat ADHD. According to Pfizer's press release, Quillivant XR is expected to be available in pharmacies in January, after receiving FDA approval in September.
Pfizer announced its intention to acquire NextWave Pharma in October, saying it would pay $255 million to NextWave's shareholders at the closing of the transaction and up to $425 million if certain sales milestones are reached. Pfizer made a $20 million option payment to NextWave in the second quarter of this year.
Tim Brugger has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.
3 Scorching-Hot Healthcare Stocks -- Are They Buys?
These three companies gained at least 400% in 2017. Can the good times continue?